Identification of Potential Key Genes of TGF-beta Signaling Associated with the Immune Response and Prognosis of Ovarian Cancer Based on Bioinformatics Analysis

Overview

Journal Heliyon

Specialty Social Sciences

Date 2023 Sep 4

PMID 37664697

Authors

Xiaoxue Zhang

Liping Han

Huimin Zhang

Yameng Niu

Ruopeng Liang

Affiliations

Soon will be listed here.

Abstract

Background: TGF-beta signaling is a key regulator of immunity and multiple cellular behaviors in cancer. However, the prognostic and therapeutic role of TGF-beta signaling-related genes in ovarian cancer (OV) remains unexplored.

Methods: Data of OV used in the current study were sourced from TCGA and GEO databases. Consensus clustering was applied to classify OV patients into different clusters using TGF-beta signaling-related genes. Differentially expressed genes (DEGs) between different clusters were screened by the "limma" R package. Prognostic genes were screened from DEGs by univariate Cox regression, followed by the construction of the TGF-beta signaling-related score. The prognostic value of TGF-beta signaling-related score was evaluated in both training and testing OV cohorts. Moreover, the immune status, GSEA and therapeutic response between low- and high-score groups were performed to further reveal the potential mechanisms.

Results: By consensus clustering, OV patients were classified into two clusters with different tumor immune environments. After differential expression and univariate Cox regression analyses, GMPR, PIEZO1, EMP1, CXCL13, GADD45B, SORCS2, FOSL2, PODN, LYNX1 and SLC38A5 were selected as prognostic genes. Using PCA algorithm, the TGF-beta signaling-related score of OV patients was calculated based on prognostic genes. Then OV patients were divided into low- and high-TGF-beta signaling-related score groups. We observed that the two score groups had significantly different survivals, tumor immune environments and expressions of immune checkpoints. In addition, GSEA results showed that immune-related pathways and biological processes, like chemokine signaling pathway, TNF signaling pathway and T cell migration were significantly enriched in the low-score group. Moreover, patients in the low- and high-score groups had remarkably different sensitivity to chemo- and immunotherapy.

Conclusion: For the first time, our study identified ten prognostic genes associated with TGF-beta signaling, constructed a prognostic TGF-beta signaling-related score and investigated the effect of TGF-beta signaling-related score on OV immunity and therapy. These findings may enrich our knowledge of the TGF-beta signaling in OV prognosis and help to improve the prognosis prediction and treatment strategies in OV.

Citing Articles

Potential shared gene signatures and molecular mechanisms between recurrent pregnancy loss and ovarian cancer.

Wang Y, Cai Y, Chen J, Shen W, Zhu J, Wang Q Front Oncol. 2024; 14:1445502.

PMID: 39610928 PMC: 11602398. DOI: 10.3389/fonc.2024.1445502.

Construction and validation of a prognostic model of angiogenesis-related genes in multiple myeloma.

Hu R, Chen F, Yu X, Li Z, Li Y, Feng S BMC Cancer. 2024; 24(1):1269.

PMID: 39394121 PMC: 11470605. DOI: 10.1186/s12885-024-13024-9.

SLC38A5 promotes glutamine metabolism and inhibits cisplatin chemosensitivity in breast cancer.

Shen X, Wang G, He H, Shang P, Yan B, Wang X Breast Cancer. 2023; 31(1):96-104.

PMID: 37914960 DOI: 10.1007/s12282-023-01516-8.

References

Du F, Qi X, Zhang A, Sui F, Wang X, Proud C . MRTF-A-NF-κB/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF-β. Exp Mol Med. 2021; 53(9):1366-1378. PMC: 8492728. DOI: 10.1038/s12276-021-00670-3. View

Gao L, Zhou F . Comprehensive Analysis of RUNX and TGF-β Mediated Regulation of Immune Cell Infiltration in Breast Cancer. Front Cell Dev Biol. 2021; 9:730380. PMC: 8416425. DOI: 10.3389/fcell.2021.730380. View

Keklikoglou I, Koerner C, Schmidt C, Zhang J, Heckmann D, Shavinskaya A . MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways. Oncogene. 2011; 31(37):4150-63. DOI: 10.1038/onc.2011.571. View

Zhang Y, Liang X, Zhang L, Wang D . Metabolic characterization and metabolism-score of tumor to predict the prognosis in prostate cancer. Sci Rep. 2021; 11(1):22486. PMC: 8602249. DOI: 10.1038/s41598-021-01140-6. View

Hirata E, Sahai E . Tumor Microenvironment and Differential Responses to Therapy. Cold Spring Harb Perspect Med. 2017; 7(7). PMC: 5495051. DOI: 10.1101/cshperspect.a026781. View

Liu Y, Ding Y, Nie Y, Yang M . EMP1 Promotes the Proliferation and Invasion of Ovarian Cancer Cells Through Activating the MAPK Pathway. Onco Targets Ther. 2020; 13:2047-2055. PMC: 7071728. DOI: 10.2147/OTT.S240028. View

Niogret J, Berger H, Rebe C, Mary R, Ballot E, Truntzer C . Follicular helper-T cells restore CD8-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy. J Immunother Cancer. 2021; 9(6). PMC: 8190041. DOI: 10.1136/jitc-2020-002157. View

Yang F, Tang J, Zhao Z, Zhao C, Xiang Y . Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer. Reprod Biol Endocrinol. 2021; 19(1):178. PMC: 8641226. DOI: 10.1186/s12958-021-00860-8. View

Bessho T, Okada T, Kimura C, Shinohara T, Tomiyama A, Imamura A . Novel Characteristics of Trypanosoma brucei Guanosine 5'-monophosphate Reductase Distinct from Host Animals. PLoS Negl Trop Dis. 2016; 10(1):e0004339. PMC: 4701174. DOI: 10.1371/journal.pntd.0004339. View

10.

Li Y, Xu C, Sun B, Zhong F, Cao M, Yang L . Piezo1 promoted hepatocellular carcinoma progression and EMT through activating TGF-β signaling by recruiting Rab5c. Cancer Cell Int. 2022; 22(1):162. PMC: 9035260. DOI: 10.1186/s12935-022-02574-2. View

11.

Hao Q, Li J, Zhang Q, Xu F, Xie B, Lu H . Single-cell transcriptomes reveal heterogeneity of high-grade serous ovarian carcinoma. Clin Transl Med. 2021; 11(8):e500. PMC: 8335963. DOI: 10.1002/ctm2.500. View

12.

Natanzon Y, Goode E, Cunningham J . Epigenetics in ovarian cancer. Semin Cancer Biol. 2017; 51:160-169. PMC: 5976557. DOI: 10.1016/j.semcancer.2017.08.003. View

13.

Yang M, Lu J, Zhang G, Wang Y, He M, Xu Q . CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. J Immunother Cancer. 2021; 9(1). PMC: 7813306. DOI: 10.1136/jitc-2020-001136. View

14.

Li Z, Niu H, Qin Q, Yang S, Wang Q, Yu C . lncRNA UCA1 Mediates Resistance to Cisplatin by Regulating the miR-143/FOSL2-Signaling Pathway in Ovarian Cancer. Mol Ther Nucleic Acids. 2019; 17:92-101. PMC: 6595407. DOI: 10.1016/j.omtn.2019.05.007. View

15.

Chan M, Chung J, Chiu-Tsun Tang P, Chan A, Ho J, Lin T . TGF-β signaling networks in the tumor microenvironment. Cancer Lett. 2022; 550:215925. DOI: 10.1016/j.canlet.2022.215925. View

16.

Colak S, Ten Dijke P . Targeting TGF-β Signaling in Cancer. Trends Cancer. 2017; 3(1):56-71. DOI: 10.1016/j.trecan.2016.11.008. View

17.

Vander Ark A, Cao J, Li X . TGF-β receptors: In and beyond TGF-β signaling. Cell Signal. 2018; 52:112-120. DOI: 10.1016/j.cellsig.2018.09.002. View

18.

Ni Y, Soliman A, Joehlin-Price A, Rose P, Vlad A, Edwards R . High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition. NPJ Precis Oncol. 2021; 5(1):101. PMC: 8683510. DOI: 10.1038/s41698-021-00242-8. View

19.

Wang J, Sun D, Wang Y, Ren F, Pang S, Wang D . FOSL2 positively regulates TGF-β1 signalling in non-small cell lung cancer. PLoS One. 2014; 9(11):e112150. PMC: 4223012. DOI: 10.1371/journal.pone.0112150. View

20.

Tzavlaki K, Moustakas A . TGF-β Signaling. Biomolecules. 2020; 10(3). PMC: 7175140. DOI: 10.3390/biom10030487. View